ArticleTranslational oncology2026
Genetic evaluation of encorafenib-associated kinases RAF1 and MAPK8 in pancreatic cancer: Exploratory mediation by circulating immune traits.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPancreatic cancer (PC) is a highly lethal malignancy, and identifying actionable therapeutic targets remains crucial. RAF1 and MAPK8 are kinases linked to the in vitro pharmacological profile of encorafenib. This study investigated the associations of genetically proxied RAF1 and MAPK8 expression with PC risk and explored the potential mediating role of circulating immune traits.
methodsWe implemented a two-sample, two-step Mendelian randomization framework integrating expression quantitative trait locus data for RAF1 and MAPK8 with genome-wide association study data for PC and 731 immune cell phenotypes. Causal estimates were primarily derived using inverse-variance weighting, and mediation analysis assessed possible immune cell-dependent effects. A phenome-wide association study (PheWAS) evaluated potential genetic pleiotropy.
resultsGenetically proxied RAF1 expression (OR = 0.748, 95% CI: 0.633-0.882, P = 0.001) and MAPK8 expression (OR = 0.829, 95% CI: 0.740-0.929, P = 0.001) were significantly associated with a lower risk of PC. An activated and resting CD4+ regulatory T-cell-related phenotype showed a possible partial mediating effect. The estimated mediation proportions were 16.202% for MAPK8 and 10.607% for RAF1, suggesting that Treg-related immune variation may account for part of these associations. In the PheWAS analysis, no association reached the prespecified significance threshold, and no broad genetic pleiotropic signal was detected.
conclusionsThis study provides genetic evidence linking RAF1 and MAPK8 to PC risk. A circulating regulatory T-cell-related phenotype showed exploratory evidence of a possible partial contribution. These findings support further functional and pharmacological investigation of RAF1- and MAPK8-related pathways in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.